BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30121211)

  • 1. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
    Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
    Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2.
    Qi B; Xu X; Yang Y; Zhou Y; Chen T; Gong G; Yue X; Xu X; Hu L; He H
    Bioorg Med Chem; 2019 May; 27(10):2127-2139. PubMed ID: 30940564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
    Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
    Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
    Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
    Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors.
    Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
    Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
    Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
    Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
    Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel FLT3 kinase inhibitors.
    Pauwels D; Klaassen H; Lahortiga I; Kilonda A; Jacobs K; Sweron B; Corbau R; Chaltin P; Marchand A; Cools J
    Eur J Med Chem; 2013 May; 63():713-21. PubMed ID: 23567961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors.
    Jiao Y; Huang F; Xu P; Zhang Y; Yang S; Zhang D; Lu T; Tang W
    Med Chem; 2016; 12(4):328-37. PubMed ID: 26667231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
    Yang TH; Lee CI; Huang WH; Lee AR
    Molecules; 2017 May; 22(6):. PubMed ID: 28561780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel N
    Qi B; Yang Y; He H; Yue X; Zhou Y; Zhou X; Chen Y; Liu M; Zhang A; Wei F
    Eur J Med Chem; 2018 Feb; 146():368-380. PubMed ID: 29407963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
    Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G
    Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments.
    Su P; Wang J; Shi Y; Pan X; Shao R; Zhang J
    Bioorg Med Chem; 2015 Jul; 23(13):3228-36. PubMed ID: 25982075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.